
    
      This trial will be a prospective, randomized phase II pilot study. Consecutive patients of
      metastatic, recurrent or refractory carcinoma cervix enrolled in gynecology clinic at IRCH,
      AIIMS will be taken into study after taking informed consent. Patients will be randomized
      into two arms. Each arm shall contain 20 patients. The patients shall receive paclitaxel and
      carboplatin q3wk in first arm and paclitaxel and carboplatin q1 wk in second arm.
    
  